In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populat...

Full description

Bibliographic Details
Main Authors: Agnieszka M Szemiel, Andres Merits, Richard J Orton, Oscar A MacLean, Rute Maria Pinto, Arthur Wickenhagen, Gauthier Lieber, Matthew L Turnbull, Sainan Wang, Wilhelm Furnon, Nicolas M Suarez, Daniel Mair, Ana da Silva Filipe, Brian J Willett, Sam J Wilson, Arvind H Patel, Emma C Thomson, Massimo Palmarini, Alain Kohl, Meredith E Stewart
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-09-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009929

Internet

https://doi.org/10.1371/journal.ppat.1009929

Similar Items